Clinical Trial Update: Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Pembrolizumab in metastatic non-small cell lung cancer patients expressing PD-L1 who have their own patient-derived xenografts…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Samsung Medical Center | Conditions: Metastatic Non-Small Cell Lung Carcinoma | Phase 4 | Status: COMPLETED